The question is not only whether an ER-specific or overall BC PRS should be used, but also whether the PRS is equally appropriate for risk stratification in young and older women and whether it is even justified to use a common PRS for BRCA1 and BRCA2 PV carriers. Here, BRCA1 is linked to breast cancer.